Start the conversation
Back on June 1, shares of Minerva Neurosciences Inc. (Nasdaq: NERV) soared as much as 35.2% - and closed 21% higher - after a licensing deal revision gave the clinical-stage biotech firm a big cash infusion and control of a promising insomnia drug it's been developing.
The new partnership immediately adds to Minerva's financial muscle. And it bolsters the company's down-the-road prospects in a huge way.
It's a big development - and one that warrants another look at a company we've been talking about here for some time.
This is premium content for Private Briefing subscribers only.